Literature DB >> 15755682

PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.

Louis-Philippe Corbeil-Girard1, Arnaud F Klein, A Marie-Josée Sasseville, Hugo Lavoie, Marie-Josée Dicaire, Anik Saint-Denis, Martin Pagé, André Duranceau, François Codère, Jean-Pierre Bouchard, George Karpati, Guy A Rouleau, Bernard Massie, Yves Langelier, Bernard Brais.   

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is an adult-onset disease caused by expanded (GCN)12-17 stretches encoding the N-terminal polyalanine domain of the poly(A) binding protein nuclear 1 (PABPN1). OPMD is characterized by intranuclear inclusions (INIs) in skeletal muscle fibers, which contain PABPN1, molecular chaperones, ubiquitin, proteasome subunits, and poly(A)-mRNA. We describe an adenoviral model of PABPN1 expression that produces INIs in most cells. Microarray analysis revealed that PABPN1 overexpression reproducibly changed the expression of 202 genes. Sixty percent of upregulated genes encode nuclear proteins, including many RNA and DNA binding proteins. Immunofluorescence microscopy revealed that all tested nuclear proteins encoded by eight upregulated genes colocalize with PABPN1 within the INIs: CUGBP1, SFRS3, FKBP1A, HMG2, HNRPA1, PRC1, S100P, and HSP70. In addition, CUGBP1, SFRS3, and FKBP1A were also found in OPMD muscle INIs. This study demonstrates that a large number of nuclear proteins are sequestered in OPMD INIs, which may compromise cellular function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755682     DOI: 10.1016/j.nbd.2004.10.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  23 in total

1.  Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.

Authors:  Ayan Banerjee; Brittany L Phillips; Quidong Deng; Nicholas T Seyfried; Grace K Pavlath; Katherine E Vest; Anita H Corbett
Journal:  J Biol Chem       Date:  2019-03-05       Impact factor: 5.157

Review 2.  Myotonic dystrophy mouse models: towards rational therapy development.

Authors:  Mário Gomes-Pereira; Thomas A Cooper; Geneviève Gourdon
Journal:  Trends Mol Med       Date:  2011-07-02       Impact factor: 11.951

Review 3.  RNA-binding proteins and gene regulation in myogenesis.

Authors:  Luciano H Apponi; Anita H Corbett; Grace K Pavlath
Journal:  Trends Pharmacol Sci       Date:  2011-10-06       Impact factor: 14.819

4.  A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.

Authors:  Aymeric Chartier; Béatrice Benoit; Martine Simonelig
Journal:  EMBO J       Date:  2006-04-27       Impact factor: 11.598

Review 5.  Protein quality control in the nucleus.

Authors:  Ramon D Jones; Richard G Gardner
Journal:  Curr Opin Cell Biol       Date:  2016-03-22       Impact factor: 8.382

Review 6.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

7.  Poly(A) binding protein C1 is essential for efficient L1 retrotransposition and affects L1 RNP formation.

Authors:  Lixin Dai; Martin S Taylor; Kathryn A O'Donnell; Jef D Boeke
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

8.  Systematic analysis of cis-elements in unstable mRNAs demonstrates that CUGBP1 is a key regulator of mRNA decay in muscle cells.

Authors:  Jerome E Lee; Ju Youn Lee; Jeffrey Wilusz; Bin Tian; Carol J Wilusz
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 9.  Oculopharyngeal muscular dystrophy: a polyalanine myopathy.

Authors:  Bernard Brais
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

Review 10.  PABPN1: molecular function and muscle disease.

Authors:  Ayan Banerjee; Luciano H Apponi; Grace K Pavlath; Anita H Corbett
Journal:  FEBS J       Date:  2013-05-24       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.